These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21707627)

  • 21. Quality of life in community-dwelling patients with schizophrenia in China.
    Xiang YT; Hou YZ; Yan F; Dixon LB; Ungvari GS; Dickerson F; Li WY; Li WX; Zhu YL; Chan SS; Lee EH; Chiu HF
    J Nerv Ment Dis; 2012 Jul; 200(7):584-7. PubMed ID: 22759934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
    Wiffen BD; Rabinowitz J; Fleischhacker WW; David AS
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):169-75. PubMed ID: 20880827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Natural evolution of paranoid schizophrenia treated consecutively with 4 different neuroleptics].
    Portier A; Sarfati Y
    Encephale; 2000; 26(4):75-7. PubMed ID: 11064844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obsessive-compulsive disorder and obsessive-compulsive symptoms in Japanese inpatients with chronic schizophrenia - a possible schizophrenic subtype.
    Owashi T; Ota A; Otsubo T; Susa Y; Kamijima K
    Psychiatry Res; 2010 Oct; 179(3):241-6. PubMed ID: 20483470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditioning in the prediction of drug withdrawal effects in chronic schizophrenic patients.
    Ban TA; Ananth JV; Lehmann HE
    Act Nerv Super (Praha); 1974 Mar; 16(1):23-33. PubMed ID: 4156144
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia.
    Jeste DV; Harris MJ; Krull A; Kuck J; McAdams LA; Heaton R
    Am J Psychiatry; 1995 May; 152(5):722-30. PubMed ID: 7726312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol.
    O'Brien CP; DiGiacomo JN; Webb W
    Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Symptomatology and gender in schizophrenia].
    Usall J; Ochoa S; Araya S; Gost A; Busquets E;
    Actas Esp Psiquiatr; 2000; 28(4):219-23. PubMed ID: 11116792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interictal psychoses in comparison with schizophrenia--a prospective study.
    Tadokoro Y; Oshima T; Kanemoto K
    Epilepsia; 2007 Dec; 48(12):2345-51. PubMed ID: 17666070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of late-onset schizophrenia in Japan: comparison with early-onset cases.
    Yasuda M; Kobayashi T; Kato S; Kishi K
    Psychogeriatrics; 2013 Dec; 13(4):244-9. PubMed ID: 24289465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demographic features and premorbid personality disorder traits in relation to age of onset and sex in paranoid schizophrenia.
    Skokou M; Gourzis P
    Psychiatry Res; 2014 Mar; 215(3):554-9. PubMed ID: 24495576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paranoid and nonparanoid schizophrenic processing of facially displayed affect.
    Kline JS; Smith JE; Ellis HC
    J Psychiatr Res; 1992 Jul; 26(3):169-82. PubMed ID: 1432844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.